Patent ID: 7381720

Claim:
A method for reducing cell proliferation or inducing cell death, comprising contacting a cell with an effective amount of the compound having formula 1, or pharmaceutically acceptable salts, and esters thereof; wherein V is H, halo, NR 1 R 2 or NR 1 —(CR 1 2 ) n —NR 3 R 4 ; A is H, fluoro, or NR 1 2 ; Z is O, S, NR 1 or CH 2 ; U is selected from the group consisting of NR 1 —(CR 1 2 ) n —NR 3 R 4 and NR 1 R; X is OR 2 , NR 1 R 2 , halo, azido, or SR 2 ; n is 1-6; wherein R 1 and R 2 together with N in NR 1 R 2 and R 3 and R 4 together with N in NR 3 R 4 may independently form an optionally substituted 5-6 membered ring containing N, and optionally O or S; R is an optionally substituted 5-14 membered heterocyclic ring containing one or more N, O or S; or a C 1-10 alkyl or C 2-10 alkenyl optionally containing one or more non-adjacent heteroatoms selected from N, O, and S, and optionally substituted with an optionally substituted carbocyclic or heterocyclic ring; R 1 and R 3 are independently H or a C 1-6 alkyl; R 2 and R 4 are independently H or a C 1-10 alkyl or C 2-10 alkenyl optionally containing one or more non-adjacent heteroatoms selected from N, O, and S, and optionally substituted with a carbocyclic or heterocyclic ring; or R 2 is an optionally substituted heterocyclic ring, aryl or heteroaryl; W is selected from the group consisting of wherein Q, Q 1 , Q 2 , and Q 3 are independently CH or N; Y is independently O, CH, C═O or NR 1 ; and R 5 is a substituent at any position on the fused ring; and is H, OR 2 , C 1-6 alkyl, C 2-6 alkenyl, each optionally substituted by halo, or ═O; or two adjacent R 5 are linked to obtain a 5-6 membered substituted or unsubstituted carbocyclic or heterocyclic ring, optionally fused to an additional substituted or unsubstituted carbocyclic or heterocyclic ring; wherein each optionally substituted moiety is substituted with one or more halo, OR 2 , NR 1 R 2 , carbamate, C 1-10 alkyl, C 2-10 alkenyl, each optionally substituted by halo, ═O, aryl or one or more heteroatoms selected from N, O and S; or is substituted with an aryl, a carbocyclic or a heterocyclic ring; thereby reducing cell proliferation or inducing cell death; wherein when said contacting is in vivo, said cell is a prostate cancer cell, a colorectal cancer cell, a cervical cancer cell, a leukemia cell, or a lymphoma cell.